pulmonari
dysfunct
one
preval
caus
morbid
prematur
mortal
pediatr
cancer
studi
found
death
second
subsequ
malign
pulmonari
abnorm
detect
survivor
age
year
childhood
cancer
acut
lymphoblast
leukemia
common
carri
excel
prognosi
surviv
exceed
era
rise
cure
rate
late
pulmonari
effect
becom
increasingli
import
grow
popul
histor
research
focus
identifi
therapi
radiat
hematopoiet
stem
cell
transplant
hsct
inform
pulmonari
howev
respiratori
infect
also
signific
caus
pulmonari
morbid
particular
recent
studi
use
polymeras
chain
reaction
pcr
diagnost
found
respiratori
viral
infect
rvi
caus
febril
episod
children
undergo
chemotherapi
risk
sever
rvi
prolong
clinic
cours
higher
viral
gener
studi
respiratori
syncyti
viru
rsv
rhinoviru
hrv
bronchiol
infanc
associ
subsequ
wheez
obstruct
rvi
also
shown
precipit
late
airflow
alloimmun
lung
transplant
recipi
howev
pulmonari
sequela
rvi
children
undergo
chemotherapi
alon
investig
current
children
oncolog
group
cog
prescrib
recommend
pulmonari
function
screen
cohort
studi
aim
evalu
pulmonari
morbid
respiratori
viral
infect
chemotherapi
childhood
survivor
defin
static
lung
function
test
b
respiratori
symptom
beyond
month
posttherapi
hypothes
children
rvi
chemotherapi
would
demonstr
increas
respiratori
symptom
poorer
lung
function
compar
without
rvi
treatment
childhood
survivor
primari
age
year
least
month
posttherapi
elig
studi
exclus
criteria
includ
therapi
prescrib
cog
ltfu
includ
craniospin
irradi
hsct
proven
bacteri
fungal
respiratori
infect
microbiolog
detect
sputum
chemotherapi
development
psychosoci
preclus
determin
oncologist
oncolog
databas
review
patient
diagnos
primari
april
april
two
site
elig
patient
recruit
order
determin
onlin
random
sequenc
gener
classifi
viral
control
group
presenc
absenc
retrospect
document
rvi
chemotherapi
respect
purpos
studi
rvi
defin
microbiolog
detect
respiratori
viru
nasopharyng
aspir
sputum
specimen
associ
b
clinic
acut
respiratori
ill
defin
cough
rhinorrhoea
sore
throat
dyspnoea
tachypnoea
abnorm
lung
examin
retrospect
document
rvi
satisfi
criteria
inpati
outpati
set
includ
june
viral
cultur
immunofluoresc
use
detect
virus
rsv
hrv
cultur
adenoviru
parainfluenza
viru
influenza
b
test
human
metapneumoviru
hmpv
becam
avail
septemb
june
pcr
magna
pure
roch
use
test
aforement
virus
see
gene
respiratori
pathogen
panel
june
pcr
test
also
includ
parainfluenza
viru
bocaviru
coronavirus
particip
underw
assess
static
lung
function
test
forc
oscil
techniqu
fot
pre
postbronchodil
spirometri
bodi
plethysmographi
diffus
capac
carbon
monoxid
dlco
order
shown
b
respiratori
symptom
questionnair
particip
clinic
well
time
assess
fot
conduct
multifrequ
composit
waveform
hz
use
tremoflo
devic
thorasi
canada
accord
publish
minimum
three
technic
satisfactori
second
record
obtain
defin
stabl
tidal
breath
pattern
sign
cough
leak
glottic
closur
volum
drift
respiratori
system
resist
hz
valu
within
reactanc
hz
frequenc
depend
resist
reson
frequenc
fre
reactanc
area
ax
report
mean
valu
satisfactori
test
percent
predict
valu
fre
calcul
use
publish
refer
whilst
ax
present
raw
valu
norm
data
poorli
establish
within
age
rang
standard
spirometri
pre
postbronchodil
bodi
plethysmographi
dlco
perform
viasi
vmax
system
sensormed
yorba
linda
ca
per
atser
forc
expiratori
volum
second
forc
vital
capac
fvc
ratio
forc
expiratori
flow
express
use
global
lung
initi
refer
posit
bronchodil
respons
defin
greater
greater
ml
andor
fvc
total
lung
capac
tlc
residu
volum
rv
dlco
evalu
percent
predict
valu
per
publish
norm
due
limit
blood
sampl
dlco
valu
uncorrect
hemoglobin
children
abnorm
dlco
valu
hemoglobin
result
within
normal
limit
test
within
prior
month
accord
laboratori
protocol
pulmonari
function
result
consid
abnorm
fvc
beyond
standard
deviat
refer
mean
tlc
predict
rv
predict
rvtlc
ratio
dlco
predict
respiratori
symptom
assess
intern
studi
asthma
allergi
childhood
isaac
liverpool
respiratori
symptom
questionnair
lrsq
isaac
questionnair
evalu
presenc
atop
diseas
includ
asthma
eczema
hay
fever
associ
symptom
lrsq
consist
question
across
domain
assess
respiratori
symptom
impact
child
famili
last
month
tabl
item
score
likert
scale
everyday
total
domain
score
overal
score
previous
recommend
snore
question
domain
preval
day
night
exercis
symptom
includ
wheez
cough
dyspnoea
also
extract
respons
day
classifi
infrequ
respons
day
day
everyday
classifi
frequent
symptom
specif
analyz
consid
clinic
signific
note
primari
outcom
measur
studi
total
respiratori
system
resist
hz
determin
fot
chosen
sensit
peripher
airway
base
previou
asthma
differ
cm
consid
clinic
meaning
assum
standard
deviat
subject
per
group
total
requir
power
statist
signific
test
period
recruit
two
group
unequ
power
calcul
demonstr
patient
ratio
viral
patient
control
need
primari
comparison
viral
control
group
made
use
student
test
continu
variabl
fisher
exact
test
categor
variabl
adjust
potenti
confound
multipl
regress
model
built
lung
function
symptom
outcom
use
forward
sequenti
method
previou
rvi
retain
model
variabl
interest
covari
includ
sex
prematur
matern
smoke
site
age
diagnosi
year
posttherapi
type
risk
protocol
test
pearson
correl
test
fish
exact
test
ad
order
univari
signific
variabl
retain
p
valu
without
inflat
standard
error
greater
due
correl
year
posttherapi
age
test
p
age
test
alreadi
adjust
lung
function
endpoint
express
year
posttherapi
test
parsimoni
model
statist
perform
use
spss
version
ibm
signific
assign
p
children
treat
across
two
institut
elig
studi
patient
contact
enrol
figur
demograph
clinic
characterist
differ
patient
consent
declin
particip
tabl
baselin
characterist
studi
popul
n
display
tabl
viral
n
control
n
group
signific
differ
demograph
clinic
characterist
children
median
rang
age
year
evalu
within
studi
origin
diagnos
year
age
evalu
year
posttherapi
patient
treat
regimen
base
protocol
anzchog
studi
studi
chemotherapi
regimen
includ
methotrex
cyclophosphamid
anthracyclin
cumul
exposur
steroid
prednison
mg
dexamethason
mg
prednison
patient
receiv
addit
reconsolid
therapi
dexamethason
equival
prednison
methotrex
patient
viral
group
n
median
rang
proven
rvi
chemotherapi
ten
patient
singl
infect
two
three
four
six
seven
total
rvi
episod
document
involv
hospit
admiss
detect
outpati
set
viral
patient
admit
least
one
rvi
mean
hospit
stay
day
per
episod
commonli
detect
viru
hrv
follow
rsv
piv
influenza
parainfluenza
type
influenza
b
hmpv
adenoviru
parainfluenza
type
coronaviru
parainfluenza
type
coronaviru
children
ever
isol
rsv
ever
isol
hrv
ever
isol
hmpv
fourteen
children
coinfect
greater
virus
mean
time
last
viral
episod
lung
function
test
rang
year
accept
repeat
fot
spirometri
bodi
plethysmographi
dlco
data
obtain
subject
respect
tabl
signific
differ
lung
function
paramet
observ
viral
control
group
lung
function
test
mean
result
within
normal
limit
viral
control
group
individu
patient
viral
control
one
abnorm
lung
function
paramet
common
abnorm
reduc
dlco
mild
predict
moder
predict
degre
impair
seven
subject
decreas
reactanc
none
demonstr
abnorm
respiratori
resist
eleven
children
viral
control
fre
valu
greater
predict
two
patient
viral
control
decreas
consist
obstruct
diseas
one
subject
posit
bronchodil
respons
three
patient
mild
reduct
tlc
two
increas
rvtlc
ratio
children
abnorm
report
respiratori
symptom
asymptomat
three
children
normal
lung
function
test
demonstr
signific
respiratori
symptom
warrant
determin
respiratori
physician
demograph
clinic
lung
function
profil
patient
pulmonari
function
andor
symptomat
abnorm
detail
tabl
preval
wheez
cough
dyspnea
group
shown
tabl
differ
reach
statist
signific
largest
effect
size
found
viral
group
demonstr
threefold
increas
odd
current
wheez
vs
odd
ratio
p
nocturn
cough
vs
p
underli
asthma
could
interven
variabl
subgroup
analysi
patient
viral
control
perform
reveal
similar
result
wheez
p
nocturn
cough
p
viral
group
total
slightli
higher
overal
lrsq
score
vs
p
increas
score
across
everi
symptom
qualiti
life
domain
except
symptom
cold
equival
control
group
figur
statist
signific
reach
symptom
domain
assess
noisi
breath
chest
noisi
breath
throat
fast
breath
isaac
questionnair
result
demonstr
preval
atop
diseas
similar
viral
control
group
asthma
vs
p
allerg
rhiniti
vs
p
eczema
vs
p
knowledg
first
studi
investig
pulmonari
morbid
respiratori
virus
chemotherapi
childhood
cancer
survivor
compar
control
children
rvi
chemotherapi
ongo
respiratori
symptom
particularli
wheez
cough
although
result
reach
statist
signific
differ
static
lung
function
found
two
group
overal
pulmonari
abnorm
detect
nearli
third
survivor
evalu
year
posttherapi
note
patient
treat
without
therapi
recogn
guidelin
thu
receiv
routin
lung
function
screen
result
suggest
children
proven
rvi
chemotherapi
may
risk
develop
respiratori
symptom
threefold
increas
odd
wheez
nocturn
cough
observ
viral
group
report
higher
preval
nearli
symptom
lrsq
score
result
howev
statist
signific
studi
power
symptom
outcom
particularli
wheez
p
cough
p
moder
effect
size
consid
type
ii
error
suggest
larger
studi
warrant
futur
find
similarli
document
follow
infant
rsv
hrv
bronchiol
rvi
associ
subsequ
asthma
pathogenesi
respiratori
virus
remain
unknown
studi
implic
excess
type
immun
aberr
lung
complex
howev
highlight
studi
suggest
inher
suscept
type
respiratori
episod
includ
bacteri
infect
import
viral
studi
one
child
posit
bronchodil
respons
atopi
low
viral
control
group
suggest
differ
phenotyp
diseas
cohort
older
sever
immunosuppress
hypothes
cancer
survivor
may
suffer
direct
tissu
damag
neuroimmun
modif
respiratori
mucosa
follow
rvi
howev
studi
requir
examin
role
pathogen
bacteria
infant
bronchiol
also
remain
question
caus
effect
whether
rvi
chemotherapi
predispos
respiratori
morbid
children
defect
suscept
rvi
static
lung
function
test
found
differ
viral
control
group
isol
import
neg
find
support
conserv
manag
rvi
cancer
therapi
suggest
viral
infect
confer
airflow
defect
possibl
immunosuppress
failur
mount
inflammatori
respons
protect
scar
lung
howev
incongru
retrospect
studi
report
late
airflow
declin
associ
rvi
hsct
recipi
independ
alloimmun
lung
prolong
subsequ
airway
inflamm
propos
mechan
injuri
find
suggest
pathogenesi
rvi
immunosuppress
cohort
uniqu
remain
poorli
understood
patient
rvi
may
sever
explan
preserv
lung
function
despit
increas
respiratori
symptom
firstli
reliabl
symptom
may
question
howev
differ
outcom
observ
use
valid
questionnair
lrsq
isaac
viral
control
group
altern
lung
function
test
assess
static
physiolog
may
stress
pulmonari
system
detect
function
abnorm
possibl
cardiopulmonari
exercis
test
elev
fre
valu
cohort
previous
associ
increas
capacit
distal
airway
patholog
suggest
multipl
breath
washout
may
need
better
character
peripher
ventil
studi
also
provid
evalu
lung
function
homogen
cohort
survivor
treat
contemporari
protocol
without
hsct
chest
radiat
pulmonari
abnorm
detect
individu
half
asymptomat
common
defect
reduc
dlco
paramet
reflect
lung
may
suggest
pictur
fibrosi
although
imag
part
formal
studi
protocol
due
ethic
consider
children
abnorm
dlco
valu
four
receiv
hrct
demonstr
diffus
mild
moder
ga
trap
suggest
smaller
airway
diseas
difficult
draw
conclus
limit
sampl
find
contribut
justif
investig
five
studi
previous
report
pulmonari
function
childhood
leukemia
survivor
none
analyz
impact
respiratori
found
restrict
lung
defect
diffus
impair
patient
also
asymptomat
literatur
predat
mostli
investig
patient
treat
recogn
therapi
hsct
chest
radiat
recent
studi
leukemia
lymphoma
survivor
conduct
egyptian
institut
routin
pulmonari
function
impuls
oscillometri
ct
although
diffus
capac
assess
subclin
abnorm
detect
survivor
contrast
studi
tantawi
et
report
elev
cohort
may
due
heterogen
patient
cohort
differ
chemotherapi
regimen
pauciti
literatur
describ
lung
function
contemporari
cancer
survivor
treat
without
establish
therapi
although
primari
aim
studi
find
abnorm
nearli
third
survivor
suggest
research
warrant
investig
unrecogn
aetiolog
inform
need
respiratori
surveil
futur
ltfu
guidelin
date
one
largest
lung
function
studi
leukemia
survivor
report
examin
late
morbid
respiratori
virus
lung
function
data
collect
includ
object
pulmonari
function
measur
outcom
patient
homogen
cohort
primari
survivor
treat
contemporari
chemotherapi
protocol
exclus
children
expos
known
therapi
proven
bacterialfung
respiratori
infect
enabl
respiratori
virus
examin
minim
confound
howev
retrospect
studi
also
number
limit
rel
small
sampl
size
result
reach
statist
signific
thu
data
consid
suffici
patient
recruit
test
power
calcul
base
asthma
studi
studi
power
evalu
specif
risk
factor
virus
subspeci
preserv
parsimoni
model
covari
univari
p
could
retain
multivari
regress
analysi
thu
clinic
import
factor
age
diagnosi
retain
weak
predictor
small
sampl
size
requir
larger
studi
power
statist
model
meaning
test
impact
covari
retrospect
studi
reli
past
medic
record
microbiolog
test
sputum
sampl
collect
patient
time
therapi
data
use
classifi
viral
control
group
exclud
children
proven
respiratori
bacteri
fungal
infect
although
sputum
sampl
would
routin
test
patient
incomplet
medic
record
also
preclud
character
rvi
sever
upper
lower
tract
infect
furthermor
microbiolog
method
use
isol
respiratori
virus
variabl
cell
cultur
immunofluoresc
limit
diagnosi
specif
virus
hrv
hmpv
compar
newer
molecular
techniqu
thu
viral
cohort
may
repres
children
sever
infect
warrant
investig
virus
detect
microbiolog
method
avail
time
test
children
receiv
pulmonari
assess
prior
therapi
also
lack
longitudin
data
evalu
trend
pulmonari
function
chronolog
respiratori
symptom
respect
therapi
futur
investig
sequela
respiratori
virus
requir
prospect
longitudin
studi
diagnosi
standard
use
activ
viral
surveil
comprehens
lung
function
test
cardiopulmonari
exercis
test
multipl
breath
washout
may
help
character
underli
clinic
subclin
lung
function
deficit
understand
preval
etiolog
trajectori
pulmonari
dysfunct
adulthood
import
inform
futur
ltfu
guidelin
survivor
care
studi
found
children
respiratori
viral
infect
chemotherapi
develop
respiratori
symptom
control
howev
differ
statist
signific
differ
static
lung
function
outcom
found
two
group
overal
pulmonari
abnorm
andor
signific
ongo
respiratori
symptom
detect
nearli
third
survivor
treat
chemotherapi
evalu
year
posttreat
find
warrant
futur
prospect
studi
etiolog
clinic
signific
therapeut
option
respiratori
complic
respiratori
consid
survivor
facilit
earli
detect
manag
late
pulmonari
effect
author
declar
conflict
interest
